Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 46 - 83 |
| Updated: | 11/17/2018 |
| Start Date: | May 17, 2017 |
| End Date: | December 2024 |
Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status (APPRISE)
The primary objective is to understand the utility of Personal KinetiGraph movement recording
system data in the clinical management of Parkinson's disease (PD) in routine clinical care
at a movement disorders clinic. Specifically:
1. Measure medication use and clinical management plan changes in a large, multicenter
cohort among participants undergoing a clinical assessment with an MDS in which the MDS
reviews the participant's PKG during the clinical assessment in half of the enrolled
participants (PKG + Group) and in half of the enrolled participants the MDS completes
the clinical assessment without the PKG (PKG- Group).
2. Determine the association between frequency of medication changes, the PKG information,
and other clinical assessments among participants with and without a PKG report of their
PD motor status available to the clinician at the time of evaluation.
system data in the clinical management of Parkinson's disease (PD) in routine clinical care
at a movement disorders clinic. Specifically:
1. Measure medication use and clinical management plan changes in a large, multicenter
cohort among participants undergoing a clinical assessment with an MDS in which the MDS
reviews the participant's PKG during the clinical assessment in half of the enrolled
participants (PKG + Group) and in half of the enrolled participants the MDS completes
the clinical assessment without the PKG (PKG- Group).
2. Determine the association between frequency of medication changes, the PKG information,
and other clinical assessments among participants with and without a PKG report of their
PD motor status available to the clinician at the time of evaluation.
This is a prospective, multicenter, randomized controlled trial. The study consists of 3
phases as follows:
- Randomization phase: subjects undergo screening, baseline, interim and 90-day follow-up
visits
- PKG+ Group (standard of care clinical evaluation plus use of PKG data)
- PKG- Group (standard of care clinical evaluation without use of PKG data - the MDS
is blinded to PKG data)
- Randomization ratio will be 1:1 with assignments generated in advance of the start
of the trial by the unblinded statistician who will provide a list containing group
assignments that will be available in an Electronic Database (EDC) for site use.
- The clinical investigator, study site staff, and subject will not be blinded to the
randomization assignment during the randomization phase of the study
- Open-label phase: at the end of the 90-day randomization phase visit for PKG- Group
subjects, the MDS will report on the PKG and review it with the subject, the subject
will complete follow-ups with the MDS using the PKG information during the clinical
assessment following the same process as the PKG+ Group during the randomization phase
- Extended open-label follow-up phase: annual follow-ups for all subjects at 1, 2, and 3
years during which the MDS will use the PKG information during clinical assessments for
all subjects.
phases as follows:
- Randomization phase: subjects undergo screening, baseline, interim and 90-day follow-up
visits
- PKG+ Group (standard of care clinical evaluation plus use of PKG data)
- PKG- Group (standard of care clinical evaluation without use of PKG data - the MDS
is blinded to PKG data)
- Randomization ratio will be 1:1 with assignments generated in advance of the start
of the trial by the unblinded statistician who will provide a list containing group
assignments that will be available in an Electronic Database (EDC) for site use.
- The clinical investigator, study site staff, and subject will not be blinded to the
randomization assignment during the randomization phase of the study
- Open-label phase: at the end of the 90-day randomization phase visit for PKG- Group
subjects, the MDS will report on the PKG and review it with the subject, the subject
will complete follow-ups with the MDS using the PKG information during the clinical
assessment following the same process as the PKG+ Group during the randomization phase
- Extended open-label follow-up phase: annual follow-ups for all subjects at 1, 2, and 3
years during which the MDS will use the PKG information during clinical assessments for
all subjects.
Inclusion Criteria:
- Able and willing to sign a written informed consent for study participation
- Age 46 - 83 years at the time of consent (per PKG Indications for Use, see Technical
Instructions Manual)
- Responsive to dopaminergic medications
Exclusion Criteria:
- Contraindication to increasing dopaminergic therapy, such as current or treated
freezing gait, symptomatic postural hypotension, or bothersome hallucinations
- Wheelchair bound or bedridden
- Utilizing or planning advanced PD therapies (DBS, infusion, etc.)
- History of delirium in the past year
- In the investigator's or sponsor's opinion, subject has any unstable or clinically
significant condition that would impair the participant's ability to comply with study
requirements or interfere with interpretation of the study endpoints (e.g., subject
able to complete PKG wear instructions per Patient Instruction Manual, or ability to
comply with required study procedures and visit schedule)
We found this trial at
5
sites
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
University of Miami A private research university with more than 15,000 students from around the...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
New York University More than 175 years ago, Albert Gallatin, the distinguished statesman who served...
Click here to add this to my saved trials